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Table 1
Results Fosaprepitant vs. Control, Overall Assessment Period
Control
(n¼70)
FOS
(n¼43)
No emesis (%) 65.7 81.4
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decreased LOS, readmission at 30 days, and use of antimi-
crobials. Use of IV IST were signiﬁcantly decreased. Incor-
poration of clinical pharma should be strongly considered in
this pt population.Day(s) of melphalan (%) 98 99
Days 1-5 post-melphalan (%) 66 84
Complete response (%)
(no emesis or breakthrough antiemetic use)
1.4 4.7
Emetic episode per patient (mean) 0.76 0.28
Breakthrough antiemetic doses per patient (mean) 9.6 9.98
Complete protection (%)
(no emesis, breakthrough antiemetics,
or signiﬁcant nausea)
- 9.7*
No nausea (%)
(<5 mm on 100 mm VAS)
- 16.1*
No signiﬁcant nausea (%)
(<25 mm on 100 mm VAS)
- 35.5*
*For 31 evaluable subjects446
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Graft-versus-host-disease (GVHD) is a life threatening
complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT). The calcineurin inhibitor tacrolimus is
commonly used in combination with other immunosup-
pressants to prevent GVHD; however the optimal serum
target concentration for tacrolimus in this population re-
mains unknown. A retrospective review was conducted to
determine whether an association exists between tacrolimus
concentrations and transplant-related outcomes, speciﬁcally
acute GVHD, as well as the rate of renal toxicity and mor-
tality. Data from 203 patients who underwent an allogeneic
HSCT from a related (n¼95) or unrelated (n¼108) donor
between January 1, 2003 and December 31, 2011 at a large
academic hospital was analyzed. Sixty-two (31%) patients
developed acute GVHD within the ﬁrst 30 days following
allogeneic stem cell transplant. Median tacrolimus concen-
trations at day 0, 7, 14, and 28 were 11.2, 13.8, 13.5 and 10.2
ng/mL, respectively among those who developed acute
GVHD. Patients who did not develop acute GVHD had similar
tacrolimus concentrations of 10.4,13.1,12.3 and 9.9 ng/mL for
the same respective time points. Serum tacrolimus concen-
trationswere similar across all grades of GVHD and therewas
no correlation between drug concentrations with respect to
renal toxicity. Patients who developed renal dysfunction
(n¼18) had tacrolimus concentrations similar to the median
concentration of the entire cohort, including those who did
not experience renal toxicity. Overall mortality among the
203 included patients was 49%. Mortality was higher among
patients who developed acute GVHD (55%) than in patients
who did not experience the disease (47%). The results of this
analysis support previous conclusions that tacrolimus blood
concentrations are not associated with acute GVHD within
the ﬁrst 30 days post allogeneic HSCT.447
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Chemotherapy-induced nausea and vomiting (CINV) occurs
frequently during hematopoietic stem cell transplantation
(HSCT) despite prophylactic therapy with serotonin antago-
nists and corticosteroids. Aprepitant, an oral neurokinin-1
(NK1) inhibitor, has been considered as add-on prophylactic
therapy; however, to date no published studies have inves-
tigated the injectable NK1 inhibitor fosaprepitant (FOS) in
HSCT. The purpose of this study is to assess the ability of FOSto reduce emesis after BEAM and high-dose melphalan
autologous HSCT.
The use of a 150 mg fosaprepitant IV x 1 prior to melphalan
became standard practice at our institution in the summer of
2012 for BEAM and high-dose melphalan regimens. We
performed an IRB approved cohort study comparing patients
who prospectively receive FOS to a historical cohort who did
not receive FOS. The primary endpoint was overall percent-
age of patients with no emesis during the assessment period
(ﬁrst day of melphalan through ﬁve days after melphalan
administration). Secondary endpoints include number of
emetic episodes per patient, number of breakthrough anti-
emetic doses per patient, and complete response rate (no
emesis or breakthrough antiemetic use). Patients in the FOS
cohort also recorded nausea on a 100 mm visual analog scale
(VAS) daily allowing for additional exploratory endpoints of
complete protection rate (complete response plus no sig-
niﬁcant nausea), no signiﬁcant nausea (< 25 mm on 100 mm
VAS), and no nausea (< 5mmon 100mmVAS) to be assessed
for that single cohort. A sample size of 70 patients per cohort
was deemed necessary based on an estimated 40% no emesis
in control group for 80% power at alpha¼0.05 to detect a 25%
absolute increase in patients with no emesis.
Seventy consecutive patients who received BEAM or high-
dose melphalan without FOS were included in the historical
cohort and 43 patients have received FOS in the prospective
cohort. Interim results suggest the addition of FOS improved
the percentage of patients with no emesis and the number of
emetic episodes per patient. Exploratory endpoints in the
FOS cohort which included patient reported nausea assess-
ments on a VAS are encouraging as a third of patients re-
ported no signiﬁcant nausea during the overall assessment
period. Based on these promising interim results, enrollment
in the FOS cohort is ongoing.448
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Anti-thymocyte globulin (ATG) during conditioning for
allogeneic HSCT is often accompanied by infusion reactions;
Figure 1.
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to be established. We report our experience with a modiﬁed
infusion approach.
Between Nov 2010 and June 2013, 24 patients received rabbit
ATG for MUD allo-HSCT at our institution. From Nov 2010 -
Oct 2012 14 patients received protocol A with 2 mg/kg ATG
on days -4, -3, and -2 via titrated infusion over 4+ hrs with
methylprednisolone 60 mg IV and diphenhydramine 50 mg
PO prior to each ATG dose. From Oct 2012 - June 2013, 10
patients received protocol B whereby ATGwas over four days
(1mg/kg on day -5 and -2, 2mg/kg on days -4 and -3) at ﬁxed
rate over 20 hrs with no change to premedication; however,
additional diphenhydramine and famotidine were given
around the clock. For all patients, if ATG was held resulting in
wasting of partial dose, additional ATG was given to com-
plete total dose prescribed.
Over the course of ATG, the number of times the ATG infusion
was held due to an infusion reaction was higher for protocol
A (12 times for 14 patients) than protocol B (7 times for 10
patients). For the 14 patients on protocol A, 64% had ATG held
on day 1, 7% on day 2, and 14% on day 3. For the 10 patients on
protocol B, 20% had ATG held on day 1, 10% on day 2, and 20%
on days 3 and 4, respectively. Although the percent of pa-
tients experiencing fever, rigors, or tachycardia appeared to
be lower for protocol B on the ﬁrst two days of ATG, this was
not consistent for alterations in blood pressure or for the
third day of ATG infusion.
For each ATG day, additional doses of steroid were required
in more patients on protocol A vs. B (day one: 8 vs. 0; day
two: 2 vs. 0; day three: 5 vs. 1; day four: n/a vs. 0). The
median amount of additional steroid (in mg of methylpred-
nisolone equivalents) necessary in protocol A was 40 mg
(range 20-145) for the 8 patients treated on day one, 48 mg
(range 32-100) for the 3 patients on day two, and 80 mg
(range 30-125) for the 5 patients on day three. For protocol B,
only 1 patient required 30 mg of methylprednisolone on day
three.
No difference was noted in the number of patients who
required an additional amount of ATG to complete the
regimen (3/14 vs. 2/10). However, for protocol A the amount
of ATG administered on an additional day to complete the
regimen ranged from 11-33% of total ATG dose whereas for
protocol B the amount was 2.5-11% with one patient having
the amount added to the last day of scheduled ATG. Impor-
tantly, all patients successfully received the full amount of
ATG. No difference in time to engraftment was noted be-
tween groups.
This pilot data suggests slowing the infusion rate and
spreading the total ATG dose over 4 days with aggressive use
of antihistamine pre-medications has the potential to
decrease infusion reactions and need for additional steroid
doses. Additional patients on protocol B are being added and
results including long-term outcomes will be updated.Figure 2.449
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Stem cell mobilization and collection is a prerequisite for
ASCT. In 25-35% of patients, initial mobilization attempts fail
to harvest sufﬁcient peripheral blood stem cells (PBSC). The
standard practice was the addition of plerixafor to the
second mobilization attempt. A data-derived algorithm wasdeveloped to guide the use of plerixafor as a preemptive
strategy, at ﬁrst harvest, with the objective of preventing
ASCT delays, risk of disease progression, and reducing pa-
tient stress.
Patients and Methods: 25 patients were harvested for ASCT
in the ﬁrst year of implementation. The data-derived algo-
rithm identiﬁed patients likely to fail mobilization based on a
CD34+ cut-off for one or two ASCTs. Eight patients received
preemptive plerixafor and were compared to 6 patients who
received plerixafor as second line therapy in the previous
year.
Results: The average number of doses of ﬁlgrastim for the
second-line groupwas 16.5 vs 10.3 for the preemptive group,
a decrease of 38%. The doses of plerixafor and days of
apheresis were 2.33 vs 1.38 and 2.3 vs 1.6 for the second-line
vs the preemptive group (a 41% and 30% decrease for pre-
emptive). 83% of second-line patients proceeded to ASCT (1
progressed) vs 100% of preemptive patients at an average
number of days from ﬁrst harvest of 109 vs 47.7 days,
respectively. Engraftment was identical.
